newsfilter
← Latest News
GlobeNewswire·

Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights

Updated interim data from the upliFT-D trial in FTD-GRN demonstrated that Dose 1 PBFT02 achieved consistent elevation of CSF progranulin at six months post-treatment in the two patients with longest follow-upCompleted